Colchicine and Clinical Outcomes in Patients With Coronary Artery Disease and Elevated C-Reactive Protein: A Real-World Propensity-Matched Study

The American Journal of Cardiology 2026 Open access

Read full text
Authors: Abdallatif Dawoud, Louie B. Kamel‐Abusalha, Maddy Taylor, Mohanad Qwaider, Mohammad Safi, Rajesh Gupta, Ehab Ahmed Eltahawy
DOI: 10.1016/j.amjcard.2026.02.005
Cited by: 0
References: 9

Abstract

Inflammation is a key driver of atherosclerotic coronary artery disease (CAD), and elevated C-reactive protein (CRP) identifies patients at heightened residual inflammatory risk despite contemporary lipid-lowering and antithrombotic therapy.1–3 Randomized trials, including COLCOT and LoDoCo2, have demonstrated cardiovascular benefit with low-dose colchicine in patients with chronic or recent CAD,4,5 but data evaluating its effectiveness in real-world populations selected for elevated inflammatory burden remain limited.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Antiplatelet Therapy and Cardiovascular Diseases Atherosclerosis and Cardiovascular Diseases

Publication details

Journal / source
The American Journal of Cardiology
Volume
265
Pages
3–6
Publication date
9 February 2026
Language
EN